CSL Stock

CSL EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of CSL (CSL.AX) as of Jul 7, 2026 is 11.56.In the previous year, EV/EBIT (Enterprise Value to EBIT) was 12.45 — a change of -7.12% (lower).

EV/EBIT

11.56

YoY

-7.12%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of CSL is 2026 11.56 . EV/EBIT (Enterprise Value to EBIT) of CSL was 2025 12.45 . It decreases by -7.12% lower compared to the previous year.

The CSL EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2006
0 base
Jan 1, 2007
0 base
Jan 1, 2008
0 base
Jan 1, 2009
0 base
Jan 1, 2010
0 base
Jan 1, 2011
0 base
Jan 1, 2012
0 base
Jan 1, 2013
0 base
Jan 1, 2014
0 base
Jan 1, 2015
0 base
Jan 1, 2016
0 base
Jan 1, 2017
0 base
Jan 1, 2018
0 base
Jan 1, 2019
0 base
Jan 1, 2020
34.43 base
YEARPRICE-TO-EBIT
2026 est 7.78
2025 14.83
2024 25.99
2023 30.92
2022 33.41
2021 30.72
2020 34.43
2019 -
2018 -
2017 -
2016 -
2015 -
2014 -
2013 -
2012 -
2011 -
2010 -
2009 -
2008 -
2007 -
2006 -
Access this data via the Eulerpool API

CSL Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides CSL's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates CSL's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots CSL's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if CSL grows earnings faster than its peers.

CSL Stock analysis

What does CSL do? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CSL stock

EV/EBIT (Enterprise Value to EBIT) of CSL amounted to 12.45 11.56

Access this data via the Eulerpool API

Valuation — CSL

All Key Metrics — CSL